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Familial Alzheimer’s disease (AD), mostly associated with early onset, is caused by
mutations in three genes (APP, PSEN1, and PSEN2) involved in the production of
the amyloid β peptide. In contrast, the molecular mechanisms that trigger the most
common late onset sporadic AD remain largely unknown. With the implementation of
an increasing number of case-control studies and the upcoming of large-scale genome-
wide association studies there is a mounting list of genetic risk factors associated
with common genetic variants that have been associated with sporadic AD. Besides
apolipoprotein E, that presents a strong association with the disease (OR∼4), the rest of
these genes have moderate or low degrees of association, with OR ranging from 0.88
to 1.23. Taking together, these genes may account only for a fraction of the attributable
AD risk and therefore, rare variants and epistastic gene interactions should be taken
into account in order to get the full picture of the genetic risks associated with AD.
Here, we review recent whole-exome studies looking for rare variants, somatic brain
mutations with a strong association to the disease, and several studies dealing with
epistasis as additional mechanisms conferring genetic susceptibility to AD. Altogether,
recent evidence underlines the importance of defining molecular and genetic pathways,
and networks rather than the contribution of specific genes.
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Introduction
Alzheimer’s disease (AD) is characterized clinically by a gradual decline in memory and other cog-
nitive functions and neuropathologically by gross brain atrophy and accumulation of extracellular
amyloid plaques and intracellular neuroﬁbrillary tangles. AD is the most common cause of demen-
tia in the elderly, still without eﬀective treatment. The disease has a strong genetic component and,
in a small number of cases, AD segregates as an autosomal dominant trait in families. Although
uncommon, the identiﬁcation of these mutations in the last two or three decades has been very
critical not only for diagnosing presymptomatic individuals from autosomal dominant families,
but also for important advances in understanding AD pathobiology.
The inheritance of AD exhibits a dichotomous pattern. On one hand, early genetic linkage
family studies led to the identiﬁcation of dominantly inherited, rare mutations in the genes for
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the amyloid β precursor protein (APP), presenilin 1 (PSEN1),
and presenilin 2 (PSEN2) that are associated with early-onset AD
(EOAD) with a penetrance close to 100%. Mutations in those
three genes account for one third to one half of all autosomal
dominant cases, which in turn represent less than 1% of total AD
cases (reviewed in Guerreiro et al., 2012). On the other hand, the
risk for late onset AD (LOAD), the most common form of the dis-
ease (>95 of total cases), is inﬂuenced by common variants such
as the APOE haplotypes, as discussed below (see Table 1).
Over 30 dominant mutations in the APP gene (located at
chromosome 21q21) account for about 15% of early-onset auto-
somal dominant cases of AD. Interestingly, two recessive APP
mutations, A673V, and E693D, also reportedly cause EOAD
(Tomiyama et al., 2008; Di Fede et al., 2009). APP encodes a ubiq-
uitously expressed transmembrane protein and most mutations
cluster around or within the Aβ domain. Duplications of APP
and neighboring sequences are also linked to EOAD. Families
carrying these duplications exhibit classic AD and cerebral amy-
loid angiopathy (reviewed in Guerreiro et al., 2012). These copy
number mutations display diﬀerent frequencies depending on
the geographic population studied, being much more frequent in
Japanese than in Europeans early-onset familial cases (Raux et al.,
2005; Sleegers et al., 2006; Blom et al., 2008; Kasuga et al., 2009).
Furthermore, patients with Down syndrome, which results from
a chromosome 21 trisomy, develop AD neuropathology (Hartley
et al., 2014).
Structurally similar integral membrane proteins PSEN1 and
PSEN2 are part of the γ-secretase protein complex responsi-
ble for APP cleavage and Aβ generation (Medina and Dotti,
2003). About 80% of EOAD cases have been reported to carry
dominant, pathogenic mutations in PSEN1 (located at chromo-
some 14q24.3), whereas approximately 5% have been identiﬁed in
PSEN2, which is located at chromosome 1q31–q42 (Bird, 1999)
Mutations in PSEN1 and PSEN2 appears scattered throughout
the protein, although some clustering can be observed in the
transmembrane domains (Guerreiro et al., 2012).
On the other hand, in non-familial, sporadic cases of AD
mostly associated with late onset (LOAD), the ε4 allele of the
apolipoprotein E (APOE) gene has been identiﬁed as a major
genetic risk factor contributing to the pathogenesis of AD
(Corder et al., 1993; Strittmatter et al., 1993). The APOE gene is
located at chromosome 19q13.2 and encodes a highly pleiotropic
glycoprotein (Siest et al., 1995) involved in the transport of
cholesterol and other lipids in the periphery and brain (Mahley,
1988). There are three polymorphic alleles (ε2, ε3, and ε4) encod-
ing three isoforms that diﬀer on two amino acid residues (112
and 158): ApoE2, ApoE3 (the most common form), and ApoE4.
Presence of the ApoE4 allele increases risk in familial and spo-
radic EOAD and LOAD, increasing risk threefold when in het-
erozygosis and up to 15-fold when in homozygosis (Ashford,
2004). The ε4 allele has also a dose-dependent eﬀect on the age
at onset. Conversely, the allele ε2 appears to lowers the risk for
LOAD and delays age at onset (Corder et al., 1994).
Overall, these four genes account for 30–50% of the inheri-
tability of AD (Jonsson et al., 2012). The advent of genome-wide
association studies (GWAS) in recent years has allowed the iden-
tiﬁcation of novel genetic associations. Hence, over 20 genetic
loci have been reported to associate with increased susceptibility
for LOAD, essentially common variants with a small individual
eﬀect on risk (unlike APOE), but also recently identiﬁed rare
susceptibility variants in LOAD with larger eﬀects (see below).
Thus, besides APOE, successive GWAS analyses have gener-
ated replicable associations with LOAD for several genes: CLU,
PICALM, CR1, BIN1, CD33, MS4A cluster, CD2AP, EPHA1, and
ABCA7 (reviewed in Karch et al., 2014). A recent meta-analysis of
GWAS data from four large consortia conﬁrmed these previous
associations (except for CD33) and reported 12 new suscep-
tibility loci for AD: CASS4, CUGBP-CELF1, DSG2, FERMT2,
HLA-DRB5-DRB1, INPP5D, MEF2C, NME8, PTK2B, SLC24A4-
RIN3, SORL1, ZCWPW1 (Lambert et al., 2013; Table 1). These
genes increase AD risk in a non-Mendelian fashion, but ﬁrst-
degree relatives of LOAD patients have twice the expected risk
of AD and LOAD is more frequent in monozygotic than in
dizygotic co-twins (Reitz and Mayeux, 2014). However, the
observed risk or protective eﬀects of all the single nucleotide
polymorphisms (SNPs) tagging these 21 loci are rather small,
with odds ratio (OR) ranging from 1.22 to 0.77 (Karch et al.,
2014), and the genetic eﬀect attributable to each of these asso-
ciated loci had population-attributable fractions or preventive
fractions between 1.0 and 8.0% (Lambert et al., 2013). Although
these data are of great value to delineate the fundamental phys-
iopathological avenues of the disease, they only explain a small
proportion of familial clustering (Manolio et al., 2009). Therefore,
strong additional eﬀorts in sequencing and post-GWAS analyses
have to be put forward to ﬁnd the remaining missing heri-
tability in order to completely undercover the genetics of AD,
utterly aiming at enabling eﬀective prevention, prediction and
treatment of the disease (Manolio et al., 2009; Lambert et al.,
2013).
A number of recent excellent reviews have focused on the anal-
ysis of common genetic risk factors for LOAD and their role
in pathogenesis (Guerreiro et al., 2013a; Lambert et al., 2013;
Karch et al., 2014; Reitz and Mayeux, 2014). The genes identi-
ﬁed can be classiﬁed in a few pathways, mainly lipid metabolism,
immune response, endocytosis (Karch and Goate, 2015). Despite
the identiﬁcation of all the above-mentioned loci associated with
AD, a large proportion of the genetic component of the disor-
der remains unexplained (Lord et al., 2014). Using alternative
AD phenotypes may serve as a tool to unveil additional genes
that could modify particular aspects of the disease (Karch and
Goate, 2015). In here, we review additional mechanisms that may
at least partially explain this missing heritability such as epista-
sis, rare variants, or the presence of somatic mutations. In this
sense, this review does not intend to comprehend an exhaustive
analysis of the literature on these subjects, but to put forward
important concepts and the general evolution of the ﬁeld. The
analysis of epigenetic modiﬁcations or microRNA studies are out
of the scope of the present review.
Rare Variants
After a decade of intense eﬀorts on GWAS analysis, lately
followed by meta-analysis of studies performed on very large
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TABLE 1 | AD-associated genes.
Gene Location Protein Function
Rare variants
APP 21q21.3 Amyloid β (A4) precursor protein • β-amyloid production
• Synaptic formation and repair
• Neural plasticity
PSEN1 14q24.3 Presenilin 1 • β-amyloid production
• Notch signaling pathway
• Wnt signaling pathway
• Endoplasmic reticulum calcium ion homeostasis
PSEN2 1q42.13 Presenilin 2 • β-amyloid production
• Notch signaling pathway
ADAM10 15q22 ADAM metallopeptidase domain 10 • β-amyloid production
• Notch signaling pathway
TREM2 6p21.1 Triggering receptor expressed on myeloid cells 2 • Inflammatory response
PLD3 19q13.2 Phospholipase D family, member 3 • Lipid metabolism
AKAP9 7q21-q22 A kinase (PRKA) anchor protein 9 • Cell signaling
GRN∗ 17q21.32 Granulin • Signal transduction
• Growth factor activity
MAPT∗ 17q21.1 Microtubule-associated protein tau • Microtubule cytoskeleton organization
PRNP∗ 20p13 Prion protein • Synaptic transmission
• Neuronal copper metabolism
Common variants
APOE 19q13.2 Apolipoprotein E • Lipid metabolism
BIN1 2q14 Bridging integrator 1 • Synaptic vesicle endocitosis
• Cytoskeletal dynamics
CR1 1q32 Complement component (3b/4b) receptor 1 • Regulation of complement activation
ABCA7 19p13.3 ATP-binding cassette, sub-family A (ABC1), member 7 • Lipid metabolism
• Phagocytosis
FERMT2 14q22.1 Fermitin family member 2 • Cell-cell adhesion
• Cell spreading
• Cell shape modulation
HLA-DRB5-DRB1 6p21.3 Major histocompatibility complex, class II, DR β 5, β 1 • Immune response
CD2AP 6p12 CD2-associated protein • Regulation of actin cytoskeleton reorganization
PTK2B 8p21.1 Protein tyrosine kinase 2 β • Calcium-induced regulation of ion channels
• MAP kinase signaling pathway
INPP5D 2q37.1 Inositol polyphosphate-5-phosphatase, 145 kDa • Immune response
CUGBP-CELF1 11p11 CUGBP, Elav-like family member 1 • Regulation of RNA splicing
CD33 19q13.3 CD33 molecule • Cell signaling
SLC24A4-RIN3 14q32.12 Solute carrier family 24 (sodium/potassium/calcium
exchanger), member 4- Ras and Rab interactor 3
• Ion transmembrane transport
• Cell signaling
• Endocytosis
ZCWPW1 7q22.1 Zinc finger, CW type with PWWP domain 1 • Zinc ion binding
MEF2C 5q14.3 Myocyte enhancer factor 2C • Myogenesis
NME8 7p14.1 NME/NM23 family member 8 • Ciliary function
MS4A cluster 11q12.2 Membrane-spanning 4-domains, subfamily A • Signal transduction
EPHA1 7q34 Ephrin type-A receptor 1 • Immune response
• Neural development
PICALM 11q14 Phosphatidylinositol binding clathrin assembly protein • Clathrin-mediated endocytosis
CLU 8p21-p12 Clusterin • Lipid metabolism
• Immune response
CASS4 20q13.31 Cas scaffolding protein family member 4 • Cell–cell adhesion
• Cell spreading
SORL1 11q23.2-q24.2 Sortilin-related receptor, L(DLR class) A repeats containing • Endocytosis
• Sorting
DSG2 18q12.1 Desmoglein 2 • Cell–cell adhesion
∗GRN, MAPT, and PRNP mutations have been found in some individuals with clinical phenotypes indistinguishable from AD (Lee et al., 2014). Variants of genes associated
with Alzheimer’s disease (AD) can be classified according to their frequency as rare or common variants. Rare variants are commonly associated with early onset AD,
while common variants are associated with late onset Alzheimer’s disease (LOAD).
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cohorts, a number of common variants have been identiﬁed
to have replicable, although small eﬀects on LOAD with no
clear functionality in some cases (Cruchaga et al., 2014); and
it is unlikely that many common variants with moderate-large
eﬀects remain to be identiﬁed (Ridge et al., 2013). However, new
rare functional variants, with larger eﬀects are expected to be
associated with AD. Thus, researchers from the AD Genetics
Consortium argue that more than 25% of phenotypic variance
remains unexplained by known markers, but it is tagged by com-
mon SNPs, hence suggesting that novel ADmarkers that account
for large amounts of phenotypic variance are likely to be rare
(Ridge et al., 2013). Thus, both rare and common variants con-
tribute to AD risk (Guerreiro et al., 2013a; see Table 1). However,
GWAS are not well suited for the discovery of these rare vari-
ants, and the use of new techniques such as exome analysis or
whole genome sequencing will be required. Genome and exome
sequencing studies in large data sets are likely to add new genes
(with a moderate or low association). However, it remains to be
seen whether additional pathways can be identiﬁed (Karch and
Goate, 2015).
Besides the well-characterized mutations on PSEN1, PSEN2,
and APP found in pedigrees of familiar EOAD, the advent of new
powerful tools for genome analysis is already delivering a more
comprehensive identiﬁcation of rare variants potentially asso-
ciated with the disease. For example, whole-genome sequence
analysis from 1,795 Icelanders has led to the identiﬁcation for
the ﬁrst time of a coding mutation (A673T) in APP that protects
against AD and cognitive decline (Jonsson et al., 2012). In a dif-
ferent study, exome sequencing analysis has identiﬁed two novel
pathogenic PSEN1 mutations (p.L166V and p.S230R) in British
EOAD (Sassi et al., 2014a), although a similar study did not iden-
tify novel variants in AD in an Asian population (Chung et al.,
2014).
Additionally, rare variants in other genes previously not asso-
ciated with familiar EOAD have been found to have a high to
moderate eﬀect size. Thus, two rare, highly penetrant muta-
tions in ADAM10 (p.Q170H and p.R181G) for LOAD have been
reported (Kim et al., 2009), emphasizing the importance of whole
genome or whole exome sequencing approaches to ﬁnd rare vari-
ants causing LOAD, in addition to common variants (Jonsson
et al., 2012).
Following whole-exome sequencing and whole-genome
sequencing strategies, a rare variant in the TREM2 gene
(p.R47H) has also been associated with an increased risk of
AD with an OR of 3.4 (Guerreiro et al., 2013b; Guerreiro and
Hardy, 2013; Jonsson et al., 2013). Recently, two more TREM2
variants have been associated with either increased (p.R62H) or
decreased (p.S144G ) risk in AD (Benitez et al., 2014; Cuyvers
et al., 2014). Interestingly, TREM2 also appears to be associated
with Parkinson’s disease, frontotemporal dementia (Rayaprolu
et al., 2013; Le Ber et al., 2014), and amyotrophic lateral sclerosis
(Guerreiro and Hardy, 2013), although this remains controversial
(Slattery et al., 2014).
Applying whole exome sequencing with a family-based design
aimed at detecting novel AD risk genes, several rare, missense,
and synonymous variants in phospholipase D3 (PLD3) have been
reported to be associated with AD risk (Cruchaga et al., 2014).
One variant in PLD3 (p.V232M), which segregated with some
LOAD families appears to increase two- to threefold the risk for
AD, perhaps through its inﬂuence on APP processing (Cruchaga
et al., 2014).
Whole exome sequencing analysis performed on seven
African American AD cases, (Logue et al., 2014) has led to
ﬁnd two new rare variants in AKAP9 (A-kinase anchor protein
nine gene) potentially associated with AD, that in the replica
population from the AD Genetics Consortium showed a strong
association (rs144662445, OR = 2.75; rs149979685, OR = 3.61).
Recently, the Ibero-American Alzheimer Disease Genetics
Group Researchers analyzed the coding region and ﬂanking
sequences of APP, PSEN1, PSEN2, MAPT, and GRN by pooled-
DNA exon sequencing in 167 clinical and ﬁve autopsy-conﬁrmed,
mainly EOAD cases (Jin et al., 2012). Interestingly, pathogenic
mutations in PSEN1, GRN, and MAPT genes were found in
2.3% of the screened cases, suggesting that pathogenic muta-
tions or risk variants in MAPT and in GRN are as frequent
in clinical AD cases as mutations in APP, PSEN1, and PSEN2
(Jin et al., 2012). These ﬁndings underscore the pleotropic role
of genes such as MAPT and GRN that can inﬂuence both
frontotemporal dementia and AD (Jin et al., 2012; Lee et al.,
2014; Table 1). Likewise, missense or nonsense haplotypes in
PRNP (p.I215V or p.Q160) further highlight how very similar
genotypes in PRNP result in strikingly diﬀerent clinical pheno-
types such as prion diseases and AD (Muñoz-Nieto et al., 2013;
Guerreiro et al., 2014).
In contrast, the role of rare coding variability in Mendelian
inherited dementia genes (APP, PSEN1, PSEN2, GRN, MAPT,
and PRNP) has also been investigated in LOAD. Results indicated
that rare coding variability in PSEN1 and PSEN2 may inﬂuence
the susceptibility for LOAD, while GRN, MAPT, and PRNP do
not appear to be major contributors to LOAD (Sassi et al., 2014b).
Somatic Mutations
Advanced age is the single most important risk factor for AD.
Randomly acquired DNA damage in the nuclear genome is also
associated with aging, and post-mitotic neuronal tissue is at spe-
cial risk of DNA damage due to the elevated production of DNA-
damaging reactive oxygen species (ROS) associated with their
high metabolism (Barja, 2004; Kennedy et al., 2012). Moreover,
the mutation rate of somatic cells is roughly an order of mag-
nitude higher than mutation rates for germ-line cells (Lynch,
2010). On the other hand, evolution cannot put selective pres-
sure on those deleterious mutations that produce defects long
after the age of reproduction as it is the case of AD (Medawar,
1952; Kennedy et al., 2012). According to the so called somatic
mutation theory of aging, the accumulation of mutations in the
genetic material of somatic cells as a function of time results in
a decrease in cellular function. A signiﬁcant amount of research
has shown that somatic mutations play an important role in
aging and a number of age-related pathologies (Jeppesen et al.,
2011; Kennedy et al., 2012). Additionally, some genetic traits may
present antagonistic pleiotropy as in the case of APOE ε4 vari-
ant that appears to be associated with improved perinatal health
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and survival, favoring the selection of the ε4 allele despite its
later life deleterious eﬀects (reviewed in Eisenberg et al., 2010).
With this perspective, it is not surprising that somatic cells, espe-
cially in the brain, may accumulate a much higher proportion
of mutations in certain DNA hot spots (e.g., CpG dinucleotides)
that correlate (at a lower scale) with the reported occurrence of
pathogenic mutations in germinal-cell lines. The eﬀect of these
somatic mutations will depend on stochastic processes that allow
the generation of cellular damage that may also propagate to
other cells (Aguzzi and Rajendran, 2009). Therefore, in a wide
sense, somatic mutations could be considered as rare variants
locally generated.
Recent technological advances in the ﬁeld of genomics and
the emergence of next generation sequencing (NGS) techniques
have aggravated the diﬃculties of interpreting GWAS to reveal
the genetic basis of brain disorders. Despite a wealth of data
on candidate genes aﬀecting the susceptibility to AD and other
neurological disorders, their inherent contribution to the patho-
genesis and their relationship with non-genetic environmental
risk factors is not yet fully understood. Evidence has accumulated
showing that somatic variations can aﬀect neuronal populations
and may play a role in brain pathogenic processes. Thus, it has
been suggested that, at least in some cases copy number varia-
tions (CNV) or SNP linked to major AD and other neurological
disorders may lead to genetic dysregulation resulting in somatic
mosaicism (Iourov et al., 2013). Moreover, environmental fac-
tors may aﬀect cellular repair mechanisms and trigger a series of
events that end up generating genomic instability.
Increasing evidence has also shown that, even at low lev-
els of mosaicism, somatic mutations can cause neuropsychiatric,
and pediatric disorders such as epilepsy, autism, lissencephaly,
and intellectual disability. Interestingly, at least some of these
cases appears to have been caused by somatic mutations lim-
ited to the brain (Poduri et al., 2013). In addition, a number
of reports have shown that a signiﬁcant population of neurons
exhibit aneuploidy in both mice and humans and the level of ane-
uploidy could be as high as 1–3% in adult brain (Rehen et al.,
2005). Furthermore, brain tissue from both AD and other disor-
ders exhibits increased levels of aneuploidy when compared to
unaﬀected brain (Iourov et al., 2009; Frade and López-Sánchez,
2010).
Furthermore, a recent study has investigated the presence of
tissue-speciﬁc exonic single nucleotide variations (SNV), tak-
ing blood exome as a control (Gómez-Ramos et al., 2014).
Interestingly, the number of SNV per chromosome was indepen-
dent of chromosome size, but it was suggested to mainly relate to
the number of protein-coding genes per chromosome. Although
similar patterns of chromosomal distribution of tissue-speciﬁc
SNVswere found, clear diﬀerences were also detected, supporting
the notion that each individual tissue has a speciﬁc SNV exome
signature.
Some neurodegenerative disorders have been associated with
or can be aﬀected by somatic mutations. Thus, EOAD has been
attributed to a somatic mosaic PSEN1 mutation present in the
brain (Beck et al., 2004). Similarly, a case of sporadic Creutzfeldt–
Jakob disease has been reported to be caused by an early embry-
onic somatic mutation in the PRNP gene (Alzualde et al., 2010).
Also, patients of disorders caused by the expansion of highly
mutable repeats such as Friedrich’s ataxia or Huntington’s dis-
ease, can exhibit notable somatic heterogeneity in repeat lengths
across diﬀerent brain regions and tissues (Kahlem and Djian,
2000; Hellenbroich et al., 2001; Møllersen et al., 2010). Age-
related somatic mutations, known to play a role in cancer (Jacobs
et al., 2012), have also been proposed to be involved in normal
aging processes as well as in neurodegeneration (Kennedy et al.,
2012). Interestingly, very recent whole-exome sequencing anal-
yses of various tissues from sporadic AD patients have found
a remarkably high number of brain-speciﬁc SNV in AD hip-
pocampal samples when compared with blood (Parcerisas et al.,
2014), suggesting that somatic genetic mosaicism and brain-
speciﬁc genome reshaping may contribute to the pathogenesis of
sporadic AD.
As NGS techniques become more eﬃcient and aﬀordable in
the coming years, somatic mosaic mutations could be more read-
ily detected, and somatic mutation rates could be systematically
determined across diﬀerent regions, cell types, and time points
of the human brain development. Although the limitation of
brain tissue will still limit studies on brain-speciﬁc somatic muta-
tions, novel techniques, and improved bioinformatic analyses will
allow us to address the role of somatic mosaicism in neurologi-
cal conditions. Determining whether brain somatic mutation are
at least partially responsible for AD and other neurodegenerative
disorders will be one of the next major challenges in the ﬁeld.
Epistasis
The functional expression of certain genes may be determined
by the interaction with other genes, as well as with environ-
ment factors. Therefore, some of the missing heritability may
be conditioned by epistasis, a crucial factor to understand and
interpret genetic pathways and their functional role in complex
systems. Epistasis may refer to diﬀerent phenomena, including
the functional interaction between genes or the statistical devi-
ation from additive gene action, among others (Phillips, 2008),
yet in the context of this review, we will use the term epista-
sis as synonym of functional gene–gene interaction. However,
GWAS, whole genome and exome sequencing analyses have been
mainly focused on standard single-locus tests with diﬀerent level
of precision. With the increasing availability of genetic data deliv-
ered by the new genomic technologies, it is becoming clearer
the need to address the problems from a holistic position, taking
into account the interaction among diﬀerent players at diﬀerent
levels.
The analysis of epistasis, even if limited to the interaction
between two genes, is technically demanding and methodologi-
cally limited at present. Part of the challenge for epistasis analysis
in GWAS is the magnitude of the search and the computational
complexity associated with it (Ritchie, 2015). The methods and
related software packages used to detect the interactions between
genetic loci that contribute to human genetic disease have been
recently re-examined (Cordell, 2009). Lately, several studies have
reviewed novel advances in the methodology for detecting epis-
tasis (Ma et al., 2013; Wei et al., 2014) and discussed its relevance
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in the context of GWAS (Wei et al., 2014). A protocol for exhaus-
tive genome-wide association interaction analysis and applied to
AD has been proposed, ﬁnding replicable epistasis between the
KHDRBS2 and CRYL1 gene loci (Gusareva et al., 2014).
A powerful tool to disentangle the complexity of a disorder
such as AD is the use of the concept of endophenotypes to deﬁne
genetic association elements with more elementary phenomena
rather than with the whole spectrum of complex diagnostic enti-
ties. Therefore, markers of disease (at any level) that correlate
with a genetic trait may be useful to explore the pathophysio-
logical mechanisms related to speciﬁc aspects of the syndrome
(Cannon and Keller, 2006).
Synergy factor (SF) analysis has been used to assess over 100
claims of epistasis in sporadic LOAD, ﬁnding 27 gene–gene inter-
actions that were signiﬁcantly associated with AD (Combarros
et al., 2009). Additionally, the authors demonstrated by meta-
analysis the interaction of APOE ε4 with speciﬁc variation in four
diﬀerent genes, namelyACT, BACE1, IL6, and BCHE (Combarros
et al., 2009). More recently, a systematic review of genetic stud-
ies published between 2009 and 2012 by the Genetics Core
of the AD Neuroimaging Initiative (ADNI) focused on genetic
associations with disease status or quantitative disease endophe-
notypes including structural and functional neuroimaging, ﬂuid
biomarker assays, and cognitive performance. In this review,
the authors summarize the association of several AD risk genes
with imaging, ﬂuid and cognitive phenotypes, and indicated
the association with multiple ADNI phenotypes of several other
genes (i.e., APOC1, FTO, GRIN2B, MAGI2, and TOMM40). The
authors suggested the combination of genetic data and pheno-
types for targeting future studies employing NGS and convergent
multi-omics approaches, and for clinical drug and biomarker
development (Shen et al., 2014). Likewise, the use of neuroimag-
ing measures to deﬁne powerful quantitative endophenotypes for
exploring epistatic relationships in order to explain some of the
missing heritability in AD has been proposed (Hohman et al.,
2013). Moreover, the analysis of epistasis has also been shown to
be a key factor for genomic prediction and its application in pre-
ventive strategies through the identiﬁcation of population strata
at increased risk of disease and clinical decision making (Wray
et al., 2013).
Many studies are now focused on ﬁnding how genetic variants
inﬂuence speciﬁc traits of AD pathology, such as amyloid bur-
den (Kauwe et al., 2011, 2014; Bali et al., 2012; Hohman et al.,
2013; Shen et al., 2014), neuroﬁbrilar pathology (Kauwe et al.,
2011; Shen et al., 2014), brain atrophy (Shen et al., 2014), cog-
nitive decline (Pedraza et al., 2014), or inﬂammation (Kauwe
et al., 2014). However, the complexity and heterogeneity of AD
requires further analysis going beyond the study of single mark-
ers in isolation by taking into account interactions between genes.
For example, many of the LOAD risk genes do not show single
marker associations with amyloid pathology, but only through
interaction with other genes (e.g., BIN1 × PICALM; Hohman
et al., 2013).
Therefore, it is important to note that epistasis may be a bar-
rier to uncover the genetic basis of complex disorders, since the
eﬀects of quantitative trait loci can be masked by interactions
with other loci (Phillips, 2008). As demonstrated for GSTM3 gene
and the HHEX/IDE/KIF11 locus, the association with AD could
be purely epistatic with neither polymorphism showing an inde-
pendent eﬀect (Bullock et al., 2013). The same group, involved
in the Epistasis Project, has also reported an interaction between
transferrin andHFE genes, conﬁrming previous ﬁndings (Robson
et al., 2004) and suggesting that iron overload may be involved in
the development of AD (Lehmann et al., 2012).
Arguably, APOE is the main genetic risk factor in AD and it is
likely to interact with other genes. The epistatic eﬀect for APOE
has been recognized both in familial EOAD and LOAD modify-
ing the age at onset (Sorbi et al., 1995; Combarros et al., 2009;
Hohman et al., 2013). Using whole-trascriptome analysis of brain
gene expression, It has been demonstrated that APOE ε4 carrier
status was associated with a consistent transcriptomic shift that
resembled the LOADproﬁle (Rhinn et al., 2013). However, unlike
the genes underlying familial AD, LOAD susceptibility genes do
not speciﬁcally alter the Aβ42/40 ratios, suggesting that these
genes probably contribute to AD through distinct mechanisms
(Bali et al., 2012). Interestingly, a recent study (Naj et al., 2014)
has also demonstrated an association of APOE variants with age
at onset among aﬀected individuals with LOAD and observed
novel associations of CR1, BIN1, and PICALM with age at onset.
Along the same lines, we have explored epistasis and
pleiotropic eﬀects of various genes and neurodegenerative dis-
orders. AD and Creutzfeldt-Jakob disease (CJD) are now con-
sidered both as part of a wider group generically named as
conformational disorders, and more speciﬁcally brain amyloi-
dosis. Under the assumption that these two disorders share
common pathophysiologic mechanisms involving protein aggre-
gation in the brain leading to fatal degeneration, we investigated
a possible genetic interaction between APOE ε4 allele and the
polymorphic codon 129 of the PRNP gene in both AD and
CJD populations compared to a common control population
(Calero et al., 2011). Interestingly, we found a synergistic age-
dependent interaction between the two genes (APOE × PRNP)
in both disorders (SF = 3.59, p = 0.027 for AD; and SF = 7.26,
p = 0.005 for CJD). Our data suggest the involvement of com-
mon pathways involved in the generation, clearance, and neu-
rotoxic signal transduction of Aβ peptides and PrP in AD and
CJD. The ﬁnding of an age-dependent interaction underscores
the importance of genetic risk analysis stratiﬁed according to
other potential interacting/confounding factors such age, sex, or
comorbidities.
Finally, the comprehensive analysis of high order interactions
is limited by the exponential number of potential interactions and
our technical capacity; therefore, we need to focus on particular
subsets of the interaction space by using additional functional
information (Phillips, 2008). However, the analysis of epistasis
should not be limited only to candidate genes.
Conclusion
Over 20 loci have been associated with LOAD, deﬁning
three main routes altered in AD: lipid metabolism, immune
response, and endocytosis (see Table 1). Altogether, these
association analyses to diﬀerent genes by GWAS underscore
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the importance of deﬁning pathways and networks rather
the contribution of speciﬁc genes. Future research should be
focused on deﬁning shared and speciﬁc mechanisms among
distinct neurodegenerative and other chronic disorders includ-
ing cardiovascular disease, metabolic disorders, or even can-
cer. Further insights into complex disorders such as AD are
expected from the integration of diﬀerent -omics with detailed
high-quality clinico-physiological characterization of cases and
controls allowing the development of new disease biomark-
ers and therapeutic avenues, and will enable the implemen-
tation of personalized medicine (Ramanan and Saykin, 2013).
The identiﬁcation by GWAS of multiple disease-associated loci
of small eﬀect size emphasizes the polygenic nature of the
heritability of complex traits and common disorders such as
AD, giving rise to approach the disorder as of quantitative
dimensions instead of as a qualitative disorder (Plomin et al.,
2009).
However, a large proportion of genetic component of the dis-
order remains unexplained (Lord et al., 2014). As reviewed above,
epistasis, rare variants, and the presence of somatic mutations
are additional genetic mechanism that may explain in part this
missing heritability. Future research should emphasize: (i) the
complete characterization of the genetic risk factors including
common-low eﬀect size and rare-high eﬀect size variants, (ii) the
use of endophenotypes to associate speciﬁc traits of the disease
to genetic factors and use this information for risk prediction
and deﬁnition of treatment response groups, (iii) the analy-
sis of epistasis among diﬀerent risk genes and the interaction
with other factors such as age and sex, and (iv) the potential
pleiotropism associated with certain loci that may confer either
risk or protection to AD and may transversally regulate diﬀerent
neurodegenerative disorders. From a practical point of view, it is
important to acknowledge that most AD patients usually present
a combined pathology with other chronic disorders including
cardiovascular disease or metabolic disorders such as diabetes
mellitus type 2; and therefore we should investigate how these
pathologies interact with each other, in order to properly treat
each individual patient.
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